Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
August 28 2019 - 7:30AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical
stage biopharmaceutical company, today announced that Jerome D.
Jabbour, Chief Executive Officer, will present a company overview,
as well as host investor meetings, at the H.C. Wainwright 21st
Annual Global Investment Conference.
Date: Monday, September 9, 2019Presentation
Time: 1:45 p.m. ETPlace: Lotte New York Palace in New York City
Investors interested in arranging a meeting with
the Company's management during this conference should contact the
conference coordinator.
A live audio webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (www.matinasbiopharma.com). A webcast replay will
be accessible for 90 days following the live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical stage
biopharmaceutical company focused on the development of its lead
product candidate, MAT9001, for the treatment of cardiovascular and
metabolic conditions, and the advancement of its proprietary lipid
nano-crystal (“LNC”) platform technology for the safe delivery of
therapies previously limited by toxicity or bioavailability
issues.
MAT9001 is a prescription-only omega-3 fatty
acid-based formulation, comprised primarily of EPA and DPA, under
development for the treatment of hypertriglyceridemia. With the
support of a world-class team of clinical key opinion leaders and
regulatory consultants, MAT9001 is moving rapidly forward along a
streamlined registration pathway.
In parallel, the Company's LNC Platform is a
unique potential solution for complex challenges arising in the
delivery of both small molecules and biologics. This novel
technology allows for the delivery of life-saving compounds in ways
that can make them more tolerable, less toxic, potentially more
effective, and even orally bioavailable. The most advanced compound
using the LNC platform is MAT2203 – an orally-delivered formulation
of Amphotericin-B that has the potential to substantially improve
an otherwise challenging safety profile in critically ill
patients.
Forward-Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company's
anticipated capital and liquidity needs, strategic focus and the
future development of its product candidates, including MAT9001 and
MAT2203, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company's intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor and Media Contacts
Peter VozzoWestwicke443-213-0505peter.vozzo@westwicke.com
Ian CooneyDirector – Investor Relations &
Corporate DevelopmentMatinas Biopharma, Inc.(415)
722-4563icooney@matinasbiopharma.com
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2024 to May 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From May 2023 to May 2024